Chimeric antigen receptor, its nucleic acid, expression plastid, cell, use and composition

A chimeric antigen receptor and cell technology, applied in the field of pharmaceutical compositions for the treatment of cancer, expressing chimeric antigen receptor cells, nucleic acids encoding chimeric antigen receptors, and chimeric antigen receptors, can solve the problem of immune cell efficiency Low, unable to overcome the immunosuppressive microenvironment of solid tumors, lack of tumor-associated antigens, etc.

Active Publication Date: 2022-02-01
台湾中国医药大学附设医院
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the lack of unique tumor-associated antigens, the low efficiency of homing immune cells to tumor sites, and the inability to overcome the immunosuppressive microenvironment of solid tumors, the current cell therapy of chimeric antigen receptor immune cells makes chimeric antigen receptor Very limited efficacy in solid tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor, its nucleic acid, expression plastid, cell, use and composition
  • Chimeric antigen receptor, its nucleic acid, expression plastid, cell, use and composition
  • Chimeric antigen receptor, its nucleic acid, expression plastid, cell, use and composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] In this test example, the chimeric antigen receptor expressing cell of Example 1 of the present invention can be obtained by transducing the chimeric antigen receptor of the present invention into NK-92 cell line, and then the obtained expression of Example 1 The chimeric antigen receptor cells were analyzed by flow cytometry for the expression of chimeric antigen receptors. Please refer to image 3 , is an analysis chart of chimeric antigen receptor expression level of the chimeric antigen receptor expressing cell in Example 1 of the present invention, image 3 Among them are the expression level analysis charts of the chimeric antigen receptor of the parental NK-92 cell line that was not transduced with the chimeric antigen receptor of the present invention, and the expression of the chimeric antigen receptor cell in Example 1 at the 3rd day after transduction. Analysis chart of chimeric antigen receptor expression on day 1 and day 7. Depend on image 3 It can be s...

Embodiment 2

[0052] In this test example, the chimeric antigen receptor expressing cell of Example 2 of the present invention can be obtained by transducing the chimeric antigen receptor of the present invention into primary natural killer cells, and then the obtained expressing chimeric antigen receptor cell of Example 2 can be obtained. The chimeric antigen receptor expression level of the chimeric antigen receptor cells was analyzed by flow cytometry. Please refer to Figure 5 , is an analysis chart of chimeric antigen receptor expression in the chimeric antigen receptor expressing cells of Example 2 of the present invention. Figure 5 In the middle are the expression level analysis charts of the chimeric antigen receptor of the parental primary natural killer cells not transduced with the chimeric antigen receptor of the present invention, and the chimeric antigen receptor expressing cells of Example 2 on the third day after transduction And the analysis chart of chimeric antigen rece...

Embodiment 3

[0062] In this test example, the chimeric antigen receptor expressing cell of Example 3 of the present invention can be obtained by transducing the chimeric antigen receptor of the present invention into primary T cells, and then the obtained expressing chimeric antigen receptor cell of Example 3 can be obtained. Antigen receptor cells were analyzed by flow cytometry for the expression of chimeric antigen receptors. Please refer to Figure 7 , is an analysis chart of chimeric antigen receptor expression level of the chimeric antigen receptor expressing cell in Example 3 of the present invention, Figure 7 In the figure are the expression level analysis charts of the chimeric antigen receptor of primary T cells not transduced with the chimeric antigen receptor of the present invention, and the chimeric antigen receptor expressing cells in Example 3 on the third day and the third day after transduction 7-day chimeric antigen receptor expression analysis chart. Depend on Figu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
fluorescenceaaaaaaaaaa
fluorescenceaaaaaaaaaa
fluorescenceaaaaaaaaaa
Login to view more

Abstract

The invention discloses a chimeric antigen receptor, its nucleic acid, expression plastid, cell, application and composition. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. A chimeric antigen receptor expressing plastid can express the chimeric antigen receptor. Cells expressing chimeric antigen receptors are obtained by transducing chimeric antigen receptors into immune cells. A pharmaceutical composition for treating cancer, comprising cells expressing chimeric antigen receptors and a pharmaceutically acceptable carrier. Thus, cells expressing chimeric antigen receptors can be used to induce tumor cell death in mammals.

Description

technical field [0001] The present invention relates to a pharmaceutical product containing antigen or antibody, especially a chimeric antigen receptor, nucleic acid encoding chimeric antigen receptor, chimeric antigen receptor expressing plastid, and chimeric antigen receptor expressing cell , a pharmaceutical composition for treating cancer and uses of cells expressing chimeric antigen receptors. Background technique [0002] Cancer, also known as malignant tumor, is an abnormal proliferation of cells, and these proliferating cells may invade other parts of the body. It is a disease caused by abnormal control of cell division and proliferation mechanisms. The number of people suffering from cancer is increasing all over the world. Cancer is one of the top ten causes of death in China, and it has been the top ten cause of death for 27 consecutive years. [0003] Conventional tumor treatment methods include surgery, radiation therapy, chemotherapy, and targeted therapy. Tu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N5/10A61K35/17A61P35/00
CPCC07K16/2833C07K14/70539C12N5/0636C12N5/0646A61K35/17A61P35/00C07K2319/00C12N2510/00
Inventor 周德阳邱绍智詹佳颖潘志明黄士维
Owner 台湾中国医药大学附设医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap